Physicians' Academy for Cardiovascular Education

Wearable cardioverter-defibrillator reduced total mortality in post-MI patients with low LVEF

Efficacy of a Wearable Cardioverter-Defibrillator after Myocardial Infarction: Results of the Vest Prevention of Early Sudden Death Trial (VEST)

Presented at ACC.18 by Jeffrey Olgin (San Francisco, CA, USA)

News - Mar. 11, 2018

Main results

Conclusion

In post-MI patients with a LVEF≤35%, a WCD did not significantly reduced SCD, but was associated with a lower total mortality after 3 months. These findings indicate that WCD in high-risk patients with a low LVEF post-MI could give protection until evaluation for ICD at 40-90 days.

In a press release dr. Olgin said: ““It is possible that sudden deaths were misclassified as it’s difficult to define sudden death with accuracy when a death is unwitnessed and there is little documentation. But the cause of death is irrelevant if we can prevent it. This study found that the device was associated with fewer deaths among people recovering from a heart attack with low ejection fraction. It’s also the first therapy associated with a mortality benefit above and beyond standard medical therapy immediately after heart attack.”

Disclosures

Our coverage of ACC.18 is based on the information provided during the congress.

Share this page with your colleagues and friends: